Get the Stockscreener App
2.80
4.76%
-0.14
Celularity Inc stock is traded at $2.80, with a volume of 26,155.
It is down -4.76% in the last 24 hours and up +33.02% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
See More
Previous Close:
$2.94
Open:
$2.93
24h Volume:
26,155
Relative Volume:
0.03
Market Cap:
$63.76M
Revenue:
$14.79M
Net Income/Loss:
$-181.41M
P/E Ratio:
-5.7143
EPS:
-0.49
Net Cash Flow:
$-68.18M
1W Performance:
+24.44%
1M Performance:
+33.02%
6M Performance:
-7.28%
1Y Performance:
+36.79%
1-Day Range:
$2.80
$2.9799
1-Week Range:
$2.1183
$3.70
52-Week Range:
$1.30
$7.97
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CELU | 2.80 | 63.76M | 14.79M | -181.41M | -68.18M | -0.49 |
| VRTX | 448.94 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.42 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.97 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.19 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.82 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Celularity Partners with Genting to Build $7.2B Market-Targeting Stem Cell Facility in Bali | CELU Stock News - StockTitan
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter - The Manila Times
Celularity Resolves Nasdaq Compliance Issue, Maintains Listing After Filing Reports | CELU Stock News - StockTitan
Celularity Inc. (NASDAQ:CELU) Sees Large Increase in Short Interest - MarketBeat
After-Market Momentum: Celularity (CELU) Shares Climb On Increased Guidance - Stocks Telegraph
Celularity sets annual meeting date, stockholder proposal deadline By Investing.com - Investing.com Canada
Celularity sets annual meeting date, stockholder proposal deadline - Investing.com India
Celularity Inc. (CELU) Quarterly 10-Q Report - Quartzy
Celularity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
U.S. Stock market: Celularity(+52.68%), Applovin(+45.14%), FARO Technologies(+33.01%) and others were among the top gainers during mid day trading - Business Upturn
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million - The Manila Times
Celularity Raises 2024 Sales Forecast to $60M After Record-Breaking October Revenue | CELU Stock News - StockTitan
CELU stock touches 52-week low at $1.55 amid market fluctuations - Investing.com India
CELU stock touches 52-week low at $1.55 amid market fluctuations By Investing.com - Investing.com South Africa
Celularity reports over $24 million in biomaterial revenue By Investing.com - Investing.com Australia
Celularity Inc. Announces Anticipated Revenues for Second and Third Quarters - Defense World
Celularity reports over $24 million in biomaterial revenue - Investing.com India
Celularity Receives Nasdaq Delisting Notice Over Filing Delay - Marketscreener.com
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel - The Manila Times
Celularity reports progress on Nasdaq compliance and product sales - Investing.com
Celularity reports progress on Nasdaq compliance and product sales By Investing.com - Investing.com Australia
Celularity Provides Corporate Update - citybiz
CELUWCelularity Inc. Warrant Latest Stock News & Market Updates - StockTitan
Celularity to submit 510(k) notification for Tendon Wrap in early 2025 - TipRanks
Celularity faces Nasdaq delisting over reporting delays - Investing.com
Celularity faces Nasdaq delisting over reporting delays By Investing.com - Investing.com UK
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal - ForexTV.com
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc. - The Manila Times
Celularity expands biomaterials range with Rebound acquisition - Investing.com India
Celularity Inc SEC 10-Q Report - TradingView
Stem Cell Umbilical Cord Blood Market Report 2024, with Profiles of Cryo-Cell, Cordlife, ViaCord, CryoHoldco, LifeCell, StemCyte, Celularity Cryo-Save and Vita 34 - Yahoo Finance
Celularity (NASDAQ:CELU) Stock Price Down 8.8%Should You Sell? - MarketBeat
Amniotic Membrane Market to Grow by USD 2.7 Billion (2024-2028) with AI Impact Boosting Trends in Ophthalmic Surgery UseTechnavio Report - The Malaysian Reserve
BTIG maintains Buy rating on Cullinan Oncology stock - Investing.com
Cullinan Oncology maintains Buy rating from H.C. Wainwright with steady price target - Investing.com India
Trend Tracker for (CLS) - Stock Traders Daily
Cullinan Therapeutics (NASDAQ:CGEM) Earns Outperform Rating from Wedbush - MarketBeat
Caesars Entertainment Inc (CZR) stock: A year of ups and downs - US Post News
In the Green: Cerus Corp. (CERS) Closes at 1.97, Up/Down -4.37 from Previous Day - The Dwinnex
Creo Medical to get £25m boost from majority sale of its European business - Business Live
Medical device company to sell stake of subsidiary to Chinese manufacturerequity value of €72m - Insider Media
Objective long/short (CGEM) Report - Stock Traders Daily
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA - Yahoo Finance
Cullinan Therapeutics Inc (CGEM)’s stock price in review: A technical analysis - US Post News
(CELC) Technical Pivots with Risk Controls - Stock Traders Daily
Creo Medical Partners with Micro-Tech for Strategic Growth - TipRanks
E Fund Management Co. Ltd. Purchases New Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
State of New Jersey Common Pension Fund D Has $3.31 Million Stock Holdings in Caesars Entertainment, Inc. (NASDAQ:CZR) - Defense World
Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com - MarketBeat
Cullinan Therapeutics commences Phase 1 trial for lupus treatment By Investing.com - Investing.com Canada
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):